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Abstract
Background: Organic psychosis effects up to 70 % of patients with PD at some point yet no widely accepted scale
for this entity exists.
Methods: We developed a 10 question PD specific psychosis severity scale that we feel has good content validity.
It asks about the presence, severity, frequency, and consequences of the hallucinations (visual, auditory, olfactory)
and delusions.
Results: Fifty different PD patients with psychosis and 25 PD patients without psychosis were included, and serial
information was available in 21 of those encounters with psychosis. In psychosis subjects, results were normally
distributed: mean 17.23 (SD = 6.30). In those without psychosis 14 % scored >0, mean 0.36 [range0-7]. The intra-rater,
inter-class correlation coefficient was excellent (N = 21 pairs of observations seven days apart, ICC = 0.87). Inter-rater
reliability (two different raters, N = 46 pairs) was outstanding for the entire group, ICC = 0.92). As expected visual
hallucinations were most common (mean = 3.13). The presence of delusions was associated with greater total scores.
Conclusions: This scale, specifically designed for PD psychosis is easy to administer and has impressive metrics.
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Background
Psychosis in Parkinson’s disease (PD) affects up to 70 %
of patients, and causes tremendous morbidity [1]. The
phenotype is much different than psychosis associated
with schizophrenia or delirium. Although many different
hallucinations, illusions, and delusions are reported in
PD, the majority of episodes are visual hallucinations
(usually “benign” content of silent people or animals),
and persecutory/infidelity delusions, which are usually
more problematic [1].
Despite the prevalence and importance of PD psychosis,
no widely accepted scale exists. A Movement Disorder
Task Force evaluated scales used to assess psychosis in
PD, and concluded that a novel PD specific scale is needed
[2]. Several small scales designed specifically for PD were
felt to be insufficiently inclusive or poorly validated [3, 4],
whereas better known and validated psychosis scales were
not designed for PD psychosis and were felt to have poor
content validity [5–7].
The lack of a disease specific severity scale has probably
hampered efforts to test treatments for PD psychosis. To
this day only clozapine and pimavanserin have compelling
published efficacy data [8, 9]. To better quantify PD
psychosis and aid in future therapeutic trials, we designed
a PD specific psychosis scale and undertook psychometric
evaluations.
Methods
The main goals for this scale development were content
validity (based on the most common psychosis symptoms
in the literature and experience, as there is no gold
standard scale to compare), ease of use (10–15 minutes),
inter-rater validation to include both physicians and non-
physicians, and intra-rater validity measured over time. It
is not a specifically designed quality of life scale, although
questions 6–10 investigate how the psychosis would likely
effect quality of life (insight, affective consequences and
actions, and impact on family), nor is it designed as a
screening tool. The questions evolved over 10 years and
included patient and family input. Earlier non-validated
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versions of the scale have been used in previous clinical
trials [10, 11].
The study received a waiver from full consent from the
University of Texas Health Science Center Institutional
Review Board. All PD patients were recruited from a
movement disorder center. We included PD patients with
psychosis, based on a rating of ≥1 on UPDRS question #2,
as determined by interview with the investigator, and a
comparator group of PD patients without psychosis,
score = 0. There were no formal exclusion criteria other
than complete inability to participate. We intentionally
allowed subjects with clinical dementia but in all cases
motor symptoms preceded cognitive symptoms by more
than a year [12]. Dementia was diagnosed if patients had a
chart documented diagnosis of dementia and/or were tak-
ing acetylcholinesterase inhibitors for dementia. All con-
secutively seen psychosis patients seen in our tertiary
referral center were included, but the control group was a
convenience sample from the same clinic seen over the
same period.
The first five questions identify the type of hallucination
(visual, auditory, olfactory, sense of presence) or delusion
[Fig. 1: Scale]. The second five questions further quantify
the intensity, frequency, insight and impact of the worst
psychotic feature on the life of the patient and family. The
source of the information (patient/family/both) is docu-
mented. Since insight varies among patients, some latitude
in question semantics is allowed and we did not include a
specific question on how the psychosis affects only the pa-
tient’s quality of life. [Additional file 1: Instructions] The
final answer (0–4 for each question) is the opinion of the
interviewer. It is not self-administered.
The patients were interviewed by an experienced phys-
ician and an inexperienced coordinator who had just
started working with PD patient, at least 15 minutes apart
(inter-rater assessments). Physician interview preceded
the “inexperienced” interview in all cases. Intra-rater
reliability (test-retest) was also tested at a second point in
time 7+/−3 days after the first administration, in patients
who did not require therapeutic intervention (change in
medications) prior to then. This was done by a single
interviewer (WO).
The range of score for each specific question is 0–4 and
the total score simply adds all 10 questions. Weighted
kappa statistics were calculated for inter and intra-rater
reliability on the scale ranged 0–4 for each question, and
intra-class correlation coefficients were calculated for in-
ter- and intra-rater reliability on total score and individual
questions. We used the mixed effect model to account for
correlation within subjects. Poisson and linear model were
conducted for patients with/without psychosis and with
psychosis respectively because the total score for those
with psychosis is normally distributed but not for those
with non-psychosis [Fig. 2]. Descriptive statistics are also
presented. Analyses were performed using SAS 9.3
(SAS Institute Inc, Cary, NC) at a statistical significance
level of 0.05.
Results
On average the questionnaire required a 10 min inter-
view and family input was obtained in 84.8 % of all in-
terviews. Inter-rater testing was completed on 46
different subjects with psychosis and 25 PD patients
without psychosis. One subject was excluded because
psychosis status was not definitively marked, leaving 49,
and three psychosis subjects had intra-rater serial data,
but not inter-rater data. The mean age for all 75
subjects (51 male) was 70.0 ± 10.8 years and duration of
PD motor features was 9.4 ± 5.1 years. Dementia was
diagnosed in 26 of the 75 total subjects (34.7 %). The
PD without psychosis and PD with psychosis groups
had similar age (68.8 ± 9.1 vs 70.6 ± 11.6 years), dur-
ation of PD 8.5 ± 5.0 vs 9.9 ± 5.1 years), percent that
were male (68 % vs. 70 %), and percent that were
demented (36.0 % vs. 34.0).
For those with psychosis, the results were normally dis-
tributed with a mean score of 17.23 ± 6.30, [range: 3–32].
Only 7 of 50 questionnaires from subjects without psych-
osis scored greater than 0, and only 1 scored >3 [Fig. 2].
The inter-rater reliability was excellent for the entire group
(71 pair including psychotic and non-psychotic subjects,
ICC = 0.92). For just those with psychosis (46 pairs) the
ICC was 0.87. The intra-rater, inter-class correlation coeffi-
cient (time 1 vs. time 2 with same administrator) was excel-
lent, N = 21 pairs of observations, ICC = 0.88. As expected,
visual hallucinations were most common (mean = 3.13),
followed by sensing a presence (mean = 2.06), auditory
(mean = 1.16), and olfactory (mean = 0.29) [Table 1]. A
delusion (question #5) was scored as >0 in 36/100 PD
psychosis questionnaires. The total score in these cases
with any delusion was much higher than those with pure
hallucinations without delusions (mean = 22.51 vs. 14.49,
p < 0.001, powered by higher responses in questions #6–10
(mean of 12.53 vs 7.73, p < 0.001).
Discussion
We report very good intra-rater reliability and excellent
inter-rater reliability on a 10 question scale designed
specifically for PD associated psychosis. Several content
features warrant comment. We did not include a separ-
ate question on illusions because subjects often have dif-
ficulty differentiating these from true hallucinations so it
could be “double scored”. We instruct that illusions be
included with hallucinations (almost always visual). We
did not include tactile hallucinations. These have been
reported [13, 14], but in our experience are essentially
impossible to differentiate from “actual” sensations,
which are very common in parkinsonism, and do not
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1. How frequently do you see things that other people do not see (hallucinations) ?
0.  Never
1.  Rarely
2.  Occasionally (about once per week)
3.  Frequently (more than three times per week, 50% of days)
4.  Almost always (every day)




2.  Occasionally (about once per week)
3.  Frequently (more than three times per week, 50% of days)
4.  Almost always (every day)
3. How frequently do you hear things that other people do not hear, and that possibly are not 
there (hallucinations) ?
0.  Never
1.  Rarely (less than once per week)
2.  Occasionally (at least once per week)
3.  Frequently (more than three times per week, 50% of days)
4.  Almost always (more than once per day)
4. How frequently do you sense a presence that other people do not sense, for example 
someone is behind you but you don’t actually see them (hallucinations) ?
0.  Never
1.  Rarely
2.  Occasionally (about once per week)
3.  Frequently (more than three times per week, 50% of days)
4.  Almost always (more than once per day)
5. Do you ever feel cheated or persecuted by people, examples include a spouse that is 
unfaithful or that some people are trying to harm you for no reason?
0. No
1. Occasionally I feel this but I know it is not true
2. Often I feel this but I know it is not true
3. Occasionally I feel this and am sure it is true
4. Often I feel this and am sure it is true
6. When you do, for example, see, hear smell, sense a presence, or feel cheated, for how long 
will it typically last during that episode? (score the worst of Questions 1-5) 
0. I do not see, hear of sense any presence
1. just a second
2. seconds (2-59 seconds)
3. minutes (1-59 minutes)
4. hours (>59 minutes)
7. Can you tell that these things (hallucinations/delusions) [ask about whichever is most 
prominent] are not real ?
0.  I am not having any now
1.  I have them, but can always tell they are not real
2.  after talking to other people who say they are not real, I am convinced they are 
definitely not real
3.  after talking to other people who say they are not real, I am not sure if they are real
4.  after talking to other people who say they are not real, I still definitely feel that they 
are real
8. When you have the hallucinations, do the hallucinations ever threaten you in any way ? This 
means their actions against you, not just the fact that they are there.





9. Do you try to communicate or interact with the hallucinations ?





10. How upset or concerned is your family about the hallucinations.  If your family does not know 
about them, how upset do you think they would be about the hallucinations ?
0.  Not concerned at all
1.  Mildly concerned
2.  Moderately concerned
3.  Markedly concerned
4.  Extremely concerned        
Fig. 1 Actual Scale
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respond similarly to interventions to reduce psychosis
(dopamine dose reduction, addition of anti-psychotic
medications), suggesting they are intrinsically different
and perhaps not best thought of as “hallucinations”. It is
also our opinion that they do not contribute much to
morbidity. “Passage” (very brief ) hallucinations/illusions
are differentiated from more prolonged visual hallucina-
tions in the duration score. Delusions are usually the
most problematic psychosis. We have only a single ques-
tion on amount of delusions, compared to four regard-
ing different hallucinations, but hypothesized that the
final five questions regarding how the psychosis affects
the patient would score higher on subjects with delu-
sions, and compensate for the single delusion question.
Even if question #5 (delusions) is excluded from the total
score summation, patients who scored >0 on #5 had
significantly higher scores (p < 0.001). The last question
regarding impact on family was included to account for
the poor insight many patients possess, the fact that
families are often more disturbed by psychosis than the
patient, and because some of the major consequences of
psychosis, such as nursing home placement, are often








a score of >0
(out of 50
assessments)
Inter-Rater Reliability (95 % CI)a Intra-Rater Reliability (95 % CI)b
All (N = 71) Psychosis patients
(N = 46)
Psychosis (N = 17)
1. Frequency Visual 3.13 (0.98) 1 0.85 (0.79, 0.91) 0.62 (0.47, 0.77) 0.51 (0.23, 0.80)
2. Frequency Olfactory 0.29 (0.65) 2 0.85 (0.70, 1.00) 0.84 (0.66,1.00) 0.66 (0.47, 0.86)
3. Frequency Auditory 1.16 (1.50) 0 0.76 (0.66, 0.85) 0.72 (0.60, 0.83) 0.68 (0.51, 0.85)
4. Frequency Presence 2.06 (1.41) 4 0.79 (0.71, 0.87) 0.70 (0.58, 0.82) 0.72 (0.54, 0.90)
5. Delusion Assessment 0.97 (1.41) 2 0.64 (0.47, 0.81) 0.59 (0.40, 0.45) 0.65 (0.33, 0.97)
6. Duration of Psychosis 2.66 (0.90) 4 0.82 (0.73, 0.90) 0.59 (0.42, 0.77) 0.46 (0.15, 0.77)
7. Insight 2.03 (0.97) 2 0.75 (0.65, 0.86) 0.58 (0.41, 0.76) 0.65 (0.48, 0.82)
8. Threatening 1.34 (0.60) 0 0.82 (0.73, 0.91) 0.62 (0.43, 0.80) 0.77 (0.47, 1.00)
9. Interaction 1.71 (0.82) 0 0.81 (0.73, 0.90) 0.62 (0.45, 0.80) 0.37 (0.07, 0.66)
10. Family Concern 1.90 (1.42) 0 0.86 (0.78, 0.94) 0.80 (0.68, 0.92) 0.86 (0.73, 0.99)
TOTAL 17.23 (6.30) 7 0.92 (0.89, 0.94) 0.87 (0.80, 0.92) 0.86 (0.80, 0.91)
Weighted kappa statistics for each of 10 specific questions and intra-class correlation coefficients (ICC) for total score were shown as Inter- aand
Intra-rater breliability
Fig. 2 Histogram of Total Scores N = 100 scales with psychosis and 50 scales without psychosis
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determined by the caregivers. Since patients themselves
have markedly variable insight into their own hallucina-
tions, asking impact of their own psychosis would be dif-
ficult to quantify. We also did not exclude patients with
varying degrees of cognitive impairment, who may
further require family input. We did not formally assess
cognition at time of assessment so can’t statistically
compare “demented” vs “not-demented” subject results.
Our scale has several potential weaknesses. Data on test-
retest reliability was skewed towards subjects with less severe
psychosis, as more severe subjects required immediate inter-
ventions, and therefore could not be reassessed for this pur-
pose. We did not compare our results to any validated
general psychosis study (content validity) because their con-
tent was not designed for the PD psychosis phenotype so
any subsequent interpretation of “content” validity would
have limited utility. Content validity was excellent based on
UPDRS psychosis question (mean 17.23 for score >0 vs. 0.36
for 0) We did not formally assess sensitivity to change with
intervention, although several subjects started on clozapine
showed marked reduction in scores (data not shown).
The final 10 question set was created over a decade and in-
cluded patient and family input, however they were not for-
mally culled from a larger set and did not undergo cognitive
pre-testing. We included subjects with dementia, as this is
common in hallucinating patients, so family input was abso-
lutely necessary in this group, as demented subjects could
not understand or respond to some of the questions by
themselves. No subject had psychosis in the absence of dopa-
minergic medications, but we did not attempt to exclude the
clinical diagnosis of dementia with Lewy bodies, except by
onset of motor vs. cognitive symptoms. Importantly, the
questionnaire is not meant to be self-administered and some
interpretation of response is needed by the interviewer
(discussed more fully in the Additional file 1: Instructions),
nor is it meant to be a screening tool to diagnose psychosis.
Future research could formally assess sensitivity to treatment
response, correlations with other scales assessing quality of
life, other scales for psychosis, formal comparison of demen-
ted vs. non-demented patients, comparison of patient vs
family scores, and neurophysiology correlates.
Conclusion
We feel this scale offeres very good content valisity, in-
ter- and intra-rater reliability and ease of use.
Additional file
Additional file 1: Instructions for completing the psychosis scale.
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